J. Hanson

发表

PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1

John Woulfe, Amin Kassam, A. Kassam, 2013, Oncotarget.

Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17

P. Gibbs, N. Pavlakis, D. Tu, 2014 .

CTG / AGITG CO . 17 Results from NCIC − − Treatment of Advanced Colorectal Cancer , and PTEN Status and Benefit from Cetuximab in the PIK 3 CA , BRAF

M. Moore, J. Zalcberg, J. Simes, 2014 .

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

P. Gibbs, N. Pavlakis, D. Tu, 2013, Clinical Cancer Research.

Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor

G. Goss, I. Lorimer, J. Dimitroulakos, 2005, Clinical Cancer Research.

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases

M. Clemons, M. Daneshmand, S. Dent, 2012, ISRN oncology.

BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.

M. Daneshmand, S. Verma, J. Weberpals, 2012, Oncology letters.

Induction of senescence in primary glioblastoma cells by serum and TGFβ

T. Perkins, I. Lorimer, Alexander Gont, 2017, Scientific Reports.

Inhibition of glioblastoma malignancy by Lgl1

A. Kassam, G. Nicholas, J. Woulfe, 2014, Oncotarget.

Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma Multiforme through de-repression of Bcl-xL translation

M. Holcik, F. Roncaroli, I. Lorimer, 2013, Oncotarget.

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma

M. Daneshmand, D. Parolin, I. Lorimer, 2015, Cell cycle.

Assessment of Circulating LncRNAs Under Physiologic and Pathologic Conditions in Humans Reveals Potential Limitations as Biomarkers

D. Stewart, L. Pilote, L. McIntyre, 2016, Scientific Reports.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

C. Addison, D. Jonker, J. Bar, 2012, Clinical & Experimental Metastasis.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

C. Addison, D. Jonker, J. Bar, 2011, Clinical & Experimental Metastasis.

BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, D. Tu, 2012 .